Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HDM1005 in obesity
NCT06886126Phase 2Recruiting
- Sponsor
- Huadong Medicine
- Start
- Feb 2025
- Primary completion
- Sep 2025
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of poterepatide in obesity (5 arms), sponsored by Huadong Medicine. Primary endpoint: Percentage Change From Baseline in Body Weight at 22 weeks. Started Feb 2025; status: recruiting.
02
Drugs
poterepatide
03
Conditions
obesity
Beyond the preview
Go deeper on NCT06886126.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06886126.